JOINN Takes Big Leap into China’s CRO Future

JOINN Laboratories (昭衍新药研究中心有限公司) has a very specific vision of the future for CROs in China. “We expect a huge increase in demand for CRO services,” said John Gong, PhD, VP and CTO of JOINN in an exclusive interview with ChinaBio® Today . “In the near future, pharma will outsource 75% of its pre-clinical work, up from a level of about 25% today.” JOINN is positioning itself for the future CRO environment dominated by large, multinational pharmaceutical companies. “We would like to have preferred relationships with big pharma where we do 10-20 projects for a single company and have guaranteed income and maybe have a dedicated building for them,” said Gong. More details...